Cargando…

Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice

Detalles Bibliográficos
Autores principales:	Mattè, Alessandro, Kosinski, Penelope A., Federti, Enrica, Dang, Lenny, Recchiuti, Antonio, Russo, Roberta, Siciliano, Angela, Riccardi, Veronica, Janin, Anne, Mucci, Matteo, Leboeuf, Christophe, Iolascon, Achille, Brugnara, Carlo, De Franceschi, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483370/ https://www.ncbi.nlm.nih.gov/pubmed/36794508 http://dx.doi.org/10.3324/haematol.2022.282614

Ejemplares similares

Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis
por: Matte, Alessandro, et al.
Publicado: (2023)

P1458: MITAPIVAT AMELIORATES IN VITRO HUMAN Β THALASSEMIC ERYTHROID MATURATION INDEX AND MODULATES THE EXPRESSION OF THE CYTOPROTECTOR PEROXIREDOXIN-2.
por: Matte’, Alessandro, et al.
Publicado: (2023)

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: van Beers, E. J., et al.
Publicado: (2022)

P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: van Beers, Eduard, et al.
Publicado: (2023)

Duality of Nrf2 in iron-overload cardiomyopathy
por: Federti, Enrica, et al.
Publicado: (2023)

P1546: ACTIVATE-KIDST: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

P1547: ACTIVATE-KIDS: MITAPIVAT IN CHILDREN WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Grace, R. F., et al.
Publicado: (2022)

In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell–Related Injury
por: Federti, Enrica, et al.
Publicado: (2023)

Iron Overload in Transfusion-Dependent Indonesian Thalassemic Patients
por: Fianza, Pandji Irani, et al.
Publicado: (2021)

Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis
por: Federti, Enrica, et al.
Publicado: (2017)

Treating pyruvate kinase deficiency with Mitapivat: a short communication
por: Larik, Muhammad Omar, et al.
Publicado: (2023)

S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K. H. M., et al.
Publicado: (2022)

Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

Oxidative Stress and β-Thalassemic Erythroid Cells behind the Molecular Defect
por: De Franceschi, Lucia, et al.
Publicado: (2013)

P1483: EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE
por: Federti, E., et al.
Publicado: (2022)

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY
por: Grace, R. F., et al.
Publicado: (2022)

Adaptative Up-Regulation of PRX2 and PRX5 Expression Characterizes Brain from a Mouse Model of Chorea-Acanthocytosis
por: Federti, Enrica, et al.
Publicado: (2021)

P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS >10 G/DL
por: Grace, Rachael F., et al.
Publicado: (2023)

P1543: MITAPIVAT DECREASES THE NEED FOR TRANSFUSIONS SECONDARY TO POORLY TOLERATED ANEMIA AND ACUTE EVENTS COMPARED TO PLACEBO IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED
por: Al-Samkari, H., et al.
Publicado: (2022)

Effect of iron overload on furin expression in wild-type and β-thalassemic mice
por: Wichaiyo, Surasak, et al.
Publicado: (2015)

P1548: LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY
por: Barcellini, W., et al.
Publicado: (2022)

Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders
por: Tibaldi, Elena, et al.
Publicado: (2020)

New Therapeutic Options for the Treatment of Sickle Cell Disease
por: Matte, Alessandro, et al.
Publicado: (2019)

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT
por: Al-Samkari, H., et al.
Publicado: (2022)

Study of behavioral problems in multi-transfused thalassemic children
por: Hongally, Chandrashekar, et al.
Publicado: (2012)

Direct antiglobulin test positivity in multi-transfused thalassemics
por: Jain, Ashish, et al.
Publicado: (2016)

P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice
por: Settakorn, Kornvipa, et al.
Publicado: (2022)

Dietary ω-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis
por: Valenti, Maria Teresa, et al.
Publicado: (2021)

P1586: COMPARISON OF FREQUENCY OF TRANSFUSION RELATED COMPLICATIONS IN THALASSEMIC AND NON-THALASSEMIC PATIENTS RECEIVING NON LEUKODEPLETED RED CELL CONCENTRATE.
por: Imran, Tanzeel, et al.
Publicado: (2023)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

Atrial and ventricular function in thalassemic patients with supra-ventricular arrhythmias
por: Monte, Ines, et al.
Publicado: (2009)

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
por: Rossato, Paolo, et al.
Publicado: (2022)

Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
por: Musallam, Khaled M., et al.
Publicado: (2022)

Efficacy and Safety of Wheat Grass in Thalassemic Children on Regular Blood Transfusion
por: Mutha, Amit S, et al.
Publicado: (2018)

High Frequency of Post-Transfusion Microchimerism Among Multi-Transfused Beta-Thalassemic Patients
por: Matsagos, Spyridon, et al.
Publicado: (2022)

Factors regulating Hb F synthesis in thalassemic diseases
por: Mastropietro, Fabrizio, et al.
Publicado: (2002)

P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
por: Kuo, K. H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9g8jvsbkjl784if3f4buojue2